<DOC>
	<DOCNO>NCT00732069</DOCNO>
	<brief_summary>Little known drug affect inflammation clot factor people receive hemodialysis . It yet know drug help prevent heart damage people undergo hemodialysis whether could increase risk heart problem . The purpose study measure certain chemical blood see chemical may change hemodialysis certain drug give .</brief_summary>
	<brief_title>Study Inflammation Oxidative Stress Persons Undergoing Dialysis</brief_title>
	<detailed_description>- Cardiovascular disease lead cause death patient chronic kidney disease undergoing hemodialysis . - Traditional risk factor adequately predict cardiovascular morbidity mortality patient chronic kidney disease . - Increased oxidative stress , inflammation impair fibrinolysis contribute cardiovascular risk chronic kidney disease patient undergoing hemodialysis . - Activation renin-angiotensin-aldosterone system ( RAAS ) may contribute oxidative stress inflammation individual chronic kidney disease - Activation kallikrein-kinin system hemodialysis may increase fibrinolysis may also contribute inflammation chronic kidney disease - Despite data clinical trial demonstrate ARBs ACE inhibitor decrease cardiovascular mortality , delay progression cardiovascular disease decrease incidence diabetes general population little known impact agent cardiovascular morbidity mortality patient end- stage renal disease ( ESRD ) undergo hemodialysis - Angiotensin-converting enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) S differ mechanisms action effect inflammatory biomarkers</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Age 18 year old On thriceweekly chronic hemodialysis least 6 month Clinically stable , adequately dialyze ( singlepool Kt/V &gt; 1.2 ) thrice weekly , polysulphone membrane least 3 consecutive month prior study Body mass index &gt; 35 mg/kg History functional transplant le 6 month prior study Use antiinflammatory medication aspirin &lt; 325 mg/d History active connective tissue disease History acute infectious disease within one month prior study AIDS ( HIV seropositivity exclusion criterion ) History myocardial infarction cerebrovascular event within 3 month Advanced liver disease Gastrointestinal dysfunction require parental nutrition Active malignancy exclude basal cell carcinoma skin History ACE inhibitorassociated cough angioedema Ejection fraction le 40 % Inability discontinue ACE inhibitor ARB Predialysis potassium repeatedly high 5.5 mmol/L ( confirm repeat blood draw ) Anticipated live donor kidney transplant Use vitamin E &gt; 60 IU/d vitamin C &gt; 500 mg/d Pregnancy , breastfeed childbearing potential History poor adherence hemodialysis medical regimen Inability provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>inflammation</keyword>
	<keyword>kallikrein-kinin</keyword>
	<keyword>angiotensin receptor blockade</keyword>
	<keyword>angiotensin convert enzyme inhibition</keyword>
	<keyword>RAAS</keyword>
	<keyword>fibrinolysis</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>